BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16460547)

  • 1. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.
    Goethaert K; Van Looveren M; Lammens C; Jansens H; Baraniak A; Gniadkowski M; Van Herck K; Jorens PG; Demey HE; Ieven M; Bossaert L; Goossens H
    Clin Microbiol Infect; 2006 Jan; 12(1):56-62. PubMed ID: 16460547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
    Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
    Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo development of carbapenem resistance in clinical isolates of Enterobacter aerogenes producing multiple beta-lactamases.
    Chen YG; Zhang Y; Yu YS; Qu TT; Wei ZQ; Shen P; Li LJ
    Int J Antimicrob Agents; 2008 Oct; 32(4):302-7. PubMed ID: 18556176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
    Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
    Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase.
    Fernández-Cuenca F; Rodríguez-Martínez JM; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Jun; 27(6):549-52. PubMed ID: 16697150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
    Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
    J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
    Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
    J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and predictors of mortality in patients with Enterobacter aerogenes bacteremia.
    Chang EP; Chiang DH; Lin ML; Chen TL; Wang FD; Liu CY
    J Microbiol Immunol Infect; 2009 Aug; 42(4):329-35. PubMed ID: 19949757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
    Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
    Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
    Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and diversity of qnr alleles in AmpC-producing Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Serratia marcescens: a multicentre study from Korea.
    Park YJ; Yu JK; Lee S; Oh EJ; Woo GJ
    J Antimicrob Chemother; 2007 Oct; 60(4):868-71. PubMed ID: 17660263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital.
    Souli M; Kontopidou FV; Papadomichelakis E; Galani I; Armaganidis A; Giamarellou H
    Clin Infect Dis; 2008 Mar; 46(6):847-54. PubMed ID: 18269335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital.
    Tumbarello M; Citton R; Spanu T; Sanguinetti M; Romano L; Fadda G; Cauda R
    J Antimicrob Chemother; 2004 Feb; 53(2):277-82. PubMed ID: 14688041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.